Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis.
Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Tosco L, et al. Among authors: tombal b. Eur Urol Focus. 2018 Apr;4(3):369-375. doi: 10.1016/j.euf.2016.12.008. Epub 2017 Jan 17. Eur Urol Focus. 2018. PMID: 28753838 Clinical Trial.
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold Olesen T, Persson BE. Tombal B, et al. Eur Urol. 2010 May;57(5):836-42. doi: 10.1016/j.eururo.2009.11.029. Epub 2009 Nov 20. Eur Urol. 2010. PMID: 19962227 Clinical Trial.
Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients.
Spahn M, Joniau S, Gontero P, Fieuws S, Marchioro G, Tombal B, Kneitz B, Hsu CY, Van Der Eeckt K, Bader P, Frohneberg D, Tizzani A, Van Poppel H. Spahn M, et al. Among authors: tombal b. Eur Urol. 2010 Jul;58(1):1-7; discussion 10-1. doi: 10.1016/j.eururo.2010.03.001. Epub 2010 Mar 17. Eur Urol. 2010. PMID: 20299147
Focal therapy in prostate cancer-report from a consensus panel.
de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, Heidenreich A, Kovacs G, Mason M, Montironi R, Mouraviev V, de Reijke T, Taneja S, Thuroff S, Tombal B, Trachtenberg J, Wijkstra H, Polascik T. de la Rosette J, et al. Among authors: tombal b. J Endourol. 2010 May;24(5):775-80. doi: 10.1089/end.2009.0596. J Endourol. 2010. PMID: 20477543
A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy.
Budiharto T, Perneel C, Haustermans K, Junius S, Tombal B, Scalliet P, Renard L, Lerut E, Vekemans K, Joniau S, Van Poppel H. Budiharto T, et al. Among authors: tombal b. Radiother Oncol. 2010 Dec;97(3):474-9. doi: 10.1016/j.radonc.2010.07.008. Epub 2010 Oct 13. Radiother Oncol. 2010. PMID: 20950879
336 results